March 2015: OCTO News


After an approved substantial protocol amendment to the eligible patient population for the TARDOX Trial, the first patient has been registered this month.


On 24th March the initial launch meeting took place. Representatives from all Stage 1 sites attended in person or via teleconference. The SCALOP-2 team would like to thank all those who spoke and provided background on pancreas cancer, the trial rationale and radiotherapy quality assurance.


The recruitment period for the trial has been extended until February 2016.

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.